2014 New Drug Approvals Hit 18-Year High

January 2, 2015 8:24 PM

15 1

2014 was a good year for pharmaceutical innovation – the best, in fact, since the industry’s all-time record of 1996. FDA approved a total of 44 drugs – 39 by CDER, and 5 by CBER (Exhibit 1). As usual, this total excludes imaging agents (i.e., Lumason and Neuraceq), and only includes the biological drugs from CBER that are of rDNA origin.

AstraZeneca AstraZeneca received the most approvals (4), which may have contributed to Pfizer Pfizer’s interest. But other companies that have been hard hit by the innovation drought scored successes as well. AbbVie AbbVie, that had not produced an NME since 2004, made a remarkable return with Vieki...

Read more

To category page